Volume 11, Issue 4 (Nov 2023)                   Res Mol Med (RMM) 2023, 11(4): 249-264 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rezaei M, Sabzali S, Satari M, Parhamfar M. Immunoinformatics Vaccine Targeting S1-NTD and HA2 Against SARS-CoV-2 and Influenza. Res Mol Med (RMM) 2023; 11 (4) :249-264
URL: http://rmm.mazums.ac.ir/article-1-538-en.html
1- Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Islamic Republic of Iran , m.rezaeibio@gmail.com
2- Department of Biology, Faculty of Science, Lorestan University, Khorramabad, Islamic Republic of IRAN
3- Department of Biophysics, Malayer University, Malayer, Iran
4- Department of microbiology, Arak university of medical science, Arak, Islamic Republic of IRAN
Abstract:   (600 Views)
Background: Two of the most challenging viruses for vaccine development are SARS-CoV-2, causing the current COVID-19 pandemic, and influenza virus (H1N1), which spreads annually, causing seasonal epidemics or increasing the pandemic risk.
Materials and Methods: In this study, we analyzed the immunodominant epitope regions in fusion peptides consisting of the Spike_S1_ N-terminal domain from SARS-CoV-2 in frame to hemagglutinin H2 (HA2) gene from influenza A virus (H1N1) and also human IFNɣ gene by two (G4S)3 linkers. A comprehensive analysis based on immunoinformatic has been conducted on prediction servers to predict T- and B-cell epitopes. In silico cloning and expression in pET-28(+) expression vector and vaccine optimization were assessed. The overall model quality was accessed, and the docking or binding affinity of the designed vaccine to the Toll-like receptor 3 was analyzed.
Results: The efficiency of the constructed vaccine confirmed by appropriate expression of the designed vaccine candidate tested by in silico cloning in pET–28(+) vector and codon optimization might increase the production of vaccine candidate into Escherichia coli strain K-12.
Conclusion: In conclusion, we suggest that this fusion peptide would be an attractive design strategy for developing a bivalent vaccine against COVID-19 and influenza as promising vaccine candidates without the need to reformulate or vaccinate each year.
Full-Text [PDF 1919 kb]   (78 Downloads)    
Type of Study: Research | Subject: Immunology
Published: 2023/11/19

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Designed & Developed by : Yektaweb